Export

You can select particular sections to be included in the output file.
EN
FR

Model List of Essential Medicines

clear Found 327 recommendations for 94 medicines and 24 therapeutic equivalents
Removed recommendations and rejected applications are shown. Hide them.
8.2. Antineoplastics and supportive medicines
  1. Abemaciclib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to palbociclib for Other specified malignant neoplasms of breast
  2. Abiraterone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 250 mg; 500 mg
    Indications
    Malignant neoplasms of prostate
  3. Afatinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung
  4. All-trans retinoic acid General information
    Section
    Targeted therapies
    • Oral > Solid: 10 mg capsule
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  5. Allopurinol General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 500 mg (as sodium) powder for injection
    • Oral > Solid: 100 mg; 300 mg
    Indications
    Tumour lysis syndrome
  6. Anastrozole General information
    Section
    Hormones and antihormones
    • Oral > Solid: 1 mg tablet
    Indications
    Malignant neoplasms of breast Other specified malignant neoplasms of breast
  7. Arsenic trioxide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  8. Asparaginase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
    • Powder for injection: 10 000 IU in vial.
    Indications
    Lymphoid leukaemia, not elsewhere classified Unspecified malignant neoplasms of unspecified sites
  9. Atezolizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion
    • Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion
    Indications
    Therapeutic equivalent to pembrolizumab for Adenocarcinoma of stomach Hepatocellular carcinoma of liver Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of bronchus or lung
  10. Axicabtagene ciloleucel General information
    Section
    Antineoplastics and supportive medicines
    • Cell suspension for infusion: 2 × 10*6 anti-CD19 CAR-positive viable T-cells per kg of body weight.
    Indications
    Diffuse large B-cell lymphomas
  11. Axitinib General information
    Section
    Targeted therapies
    • Oral > Solid > tablet: 1 mg; 3 mg; 5 mg
    Indications
    Renal cell carcinoma of kidney, except renal pelvis
  12. Azacitidine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection
    Indications
    Myeloid leukaemia
  13. Bendamustine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma Follicular lymphoma
  14. Bevacizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion
    Indications
    Hepatocellular carcinoma of liver
  15. Bicalutamide General information
    Section
    Hormones and antihormones
    • Oral > Solid: 50 mg
    Indications
    Malignant neoplasms of prostate
  16. Binimetinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to trametinib for Other specified melanoma of skin
  18. Blinatumomab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial
    Indications
    B lymphoblastic leukaemia or lymphoma, not elsewhere classified
  19. Bortezomib General information
    Section
    Targeted therapies
    • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
    Indications
    Plasma cell myeloma
  20. Calcium folinate (leucovorin calcium) General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Solid > tablet: 15 mg; 5 mg; 25 mg
    • Oral > Solid: 15 mg tablet
    • Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule
    Indications
    Burkitt lymphoma including Burkitt leukaemia Osteosarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of rectum Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon Unspecified malignant neoplasms of unspecified sites Malignant trophoblastic neoplasms of placenta
  22. Carboplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL
    Indications
    Other specified gliomas of brain Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Malignant neoplasms of hypopharynx Malignant neoplasms of nasopharynx Malignant neoplasms of oropharynx Osteosarcoma of bone or articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Germ cell tumour of testis Malignant neoplasms of nasopharynx Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of breast Retinoblastoma Malignant neoplasms of kidney, except renal pelvis
  23. Cemiplimab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion
    Indications
    Therapeutic equivalent to pembrolizumab for Adenocarcinoma of stomach Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of bronchus or lung
  25. Cisplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg per 10 mL; 20 mg per 20 mL; 50 mg per 50 mL; 100 mg per 100 mL
    • Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL
    • Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
    Indications
    Other specified gliomas of brain Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Malignant neoplasms of hypopharynx Malignant neoplasms of oropharynx Malignant neoplasms of nasopharynx Germ cell tumour of testis Osteosarcoma of bone or articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Malignant neoplasms of nasopharynx Other specified malignant neoplasms of bronchus or lung Unspecified malignant neoplasms of unspecified sites
  26. Cladribine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial
    Indications
    Langerhans cell histiocytosis
  27. Cobimetinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to trametinib for Other specified melanoma of skin
  28. Crizotinib General information
    Section
    Targeted therapies
    • Oral > Solid > capsule: 200 mg; 250 mg
    • Oral > Solid: 200 mg; 250 mg
    Indications
    Anaplastic large cell lymphoma, ALK-positive Other specified malignant neoplasms of bronchus or lung
  29. Cyclophosphamide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    • Oral > Solid > dosage form: 25 mg; 50 mg
    • Oral > Solid: 25 mg tablet
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
    Indications
    Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Other specified gliomas of brain Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Rhabdomyosarcoma primary site Malignant neoplasms of breast Other specified malignant neoplasms of breast Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma Malignant trophoblastic neoplasms of placenta Follicular lymphoma Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis
  31. Dabrafenib General information
    Section
    Targeted therapies
    • Oral > Solid: 50 mg; 75 mg
    Indications
    Other specified melanoma of skin
  32. Dacarbazine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection
    Indications
    Hodgkin lymphoma
  34. Daratumumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL
    Indications
    Plasma cell myeloma
  35. Darbepoetin alfa General information
    Section
    Supportive medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia
  36. Dasatinib General information
    Section
    Targeted therapies
    • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
    Indications
    Chronic myelogenous leukaemia, BCR-ABL1-positive
  37. Daunorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia
  38. Dexamethasone General information
    Section
    Hormones and antihormones
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
    • Oral > Liquid: 2 mg per 5 mL (as sodium phosphate)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
    • Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base
    • Oral > Solid > tablet: 4 mg (as dexamethasone base)
    Indications
    Anaplastic large cell lymphoma, ALK-negative Lymphoid leukaemia, not elsewhere classified Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-positive
  40. Dostarlimab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion
    Indications
    Other specified malignant neoplasms of corpus uteri
  41. Doxorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    • Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
    Indications
    Diffuse large B-cell lymphoma, not otherwise specified Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Rhabdomyosarcoma primary site Osteosarcoma of bone or articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site Malignant neoplasms of breast Other specified malignant neoplasms of breast Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma Follicular lymphoma Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis
  42. Doxorubicin (as pegylated liposomal) General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    Indications
    Kaposi sarcoma of unspecified primary site
  44. Encorafenib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to dabrafenib for Other specified melanoma of skin
  45. Enzalutamide General information
    Section
    Hormones and antihormones
    • Oral > Solid: 40 mg
    Indications
    Therapeutic equivalent to abiraterone for Malignant neoplasms of prostate Malignant neoplasms of prostate
  46. Epoetin alfa General information
    Section
    Supportive medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia
  47. Epoetin beta General information
    Section
    Supportive medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia
  48. Erlotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 100 mg; 150 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung
  49. Erythropoiesis-stimulating agents General information
    Section
    Supportive medicines
    • Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)
    Indications
    Drug-induced aplastic anaemia
  50. Etoposide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
    • Oral > Solid: 100 mg capsule; 50 mg capsule
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
    • Oral > Solid: 100 mg capsule
    Indications
    Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Germ cell tumour of testis Osteosarcoma of bone or articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma Malignant trophoblastic neoplasms of placenta Retinoblastoma Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis
  51. Everolimus General information
    Section
    Targeted therapies
    • Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg
    • Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg
    Indications
    Other specified gliomas of brain
  52. Filgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
    Indications
    Acquired neutropaenia
  53. Fludarabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
    • Oral > Solid: 10 mg tablet (fludarabine phosphate)
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  54. Fluorouracil General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg per mL in vial
    • Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule
    Indications
    Malignant neoplasms of nasopharynx Malignant neoplasms of rectum Malignant neoplasm metastasis in large intestine Malignant neoplasms of breast Malignant neoplasms of colon Unspecified malignant neoplasms of unspecified sites
  55. Flutamide General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate
  56. Fulvestrant General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 250 mg per 5 mL
    Indications
    Malignant neoplasms of breast
  57. Gefitinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung
  58. Gemcitabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
    Indications
    Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung
  59. Goserelin General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate
  60. Hydrocortisone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
    Indications
    Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Unspecified malignant neoplasms of unspecified sites
  61. Hydroxyurea (hydroxycarbamide) General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
    • Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
    Indications
    Squamous cell carcinoma of oropharynx Chronic myeloid leukaemia, not elsewhere classified
  62. Ibrutinib General information
    Section
    Targeted therapies
    • Oral > Solid: 140 mg
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  65. Ipilimumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion
    Indications
    Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of oesophagus Melanoma of skin Other specified malignant neoplasms of bronchus or lung
  66. Irinotecan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
    Indications
    Rhabdomyosarcoma primary site Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis
  67. Lenalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 25 mg
    Indications
    Plasma cell myeloma
  68. Lenvatinib General information
    Section
    Targeted therapies
    • Oral > Solid > capsule: 4 mg; 10 mg
    Indications
    Renal cell carcinoma of kidney, except renal pelvis
  69. Leuprorelin General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
    Indications
    Malignant neoplasms of breast Malignant neoplasms of prostate
  70. Lisocabtagene maraleucel General information
    Section
    Antineoplastics and supportive medicines
    Indications
    Therapeutic equivalent to axicabtagene ciloleucel for Diffuse large B-cell lymphomas
  71. Melphalan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    • Oral > Solid: 2 mg
    Indications
    Plasma cell myeloma
  73. Mesna General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule
    • Oral > Solid > tablet: 400 mg; 600 mg
    • Oral > Other: 600 mg
    • Oral > Solid > tablet: 400 mg
    • Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
    • Oral > Solid: 400 mg; 600 mg
    Indications
    Rhabdomyosarcoma primary site Germ cell tumour of testis Other specified malignant neoplasms of the ovary Osteosarcoma of bone or articular cartilage of unspecified sites Unspecified malignant neoplasms of unspecified sites Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis Burkitt lymphoma including Burkitt leukaemia
  75. Methylprednisolone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 40 mg in vial (as sodium succinate); 125 mg in vial (as sodium succinate)
    • Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection; 125 mg in vial (as sodium succinate) powder for injection
    Indications
    Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified
  76. Nilotinib General information
    Section
    Targeted therapies
    • Oral > Solid > capsule: 150 mg; 200 mg
    Indications
    Chronic myelogenous leukaemia, BCR-ABL1-positive
  77. Nilutamide General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate
  78. Nivolumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
    • Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion
    • Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion
    Indications
    Therapeutic equivalent to pembrolizumab for Melanoma of skin Melanoma of skin Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of oesophagus Adenocarcinoma of oesophagogastric junction Adenocarcinoma of stomach Other specified malignant neoplasms of bronchus or lung
  79. Osimertinib General information
    Section
    Targeted therapies
    • Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)
    Indications
    Other specified malignant neoplasms of bronchus or lung
  80. Oxaliplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon
  82. Palbociclib General information
    Section
    Targeted therapies
    • Oral > Solid: 75 mg; 100 mg; 125 mg
    Indications
    Other specified malignant neoplasms of breast
  83. Panitumumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL vial concentrate for solution for infusion; 20 mg per mL in 20 mL vial
    Indications
    Other specified malignant neoplasms of large intestine
  84. Pegaspargase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  85. Pegfilgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe
    Indications
    Acquired neutropaenia
  86. Pembrolizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection
    Indications
    Melanoma of skin Other specified malignant neoplasms of large intestine Malignant neoplasms of cervix uteri Adenocarcinoma of stomach Malignant neoplasms of oesophagogastric junction Squamous cell carcinoma of hypopharynx and variants Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx Squamous cell carcinoma of oropharynx Squamous cell carcinoma of nasopharynx Therapeutic equivalent to nivolumab for Melanoma of skin Renal cell carcinoma of kidney, except renal pelvis Carcinoma of breast, specialised type Squamous cell carcinoma of oesophagus Other specified malignant neoplasms of bronchus or lung
  87. Pertuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution
    Indications
    Carcinoma of breast, specialised type
  89. Prednisone General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to prednisolone for Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone for Diffuse large B-cell lymphoma, not otherwise specified Therapeutic equivalent to prednisolone for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone for Plasma cell myeloma Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-negative Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-positive Therapeutic equivalent to prednisolone for Langerhans cell histiocytosis Therapeutic equivalent to prednisolone for Hodgkin lymphoma Therapeutic equivalent to prednisolone for Malignant neoplasms of prostate Therapeutic equivalent to prednisolone for Follicular lymphoma
  90. Procarbazine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 50 mg (as hydrochloride)
    • Oral > Solid > capsule: 50 mg (as hydrochloride)
    Indications
    Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma
  91. Rasburicase General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution
    Indications
    Tumour lysis syndrome
  92. Realgar-indigo naturalis formulation General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  93. Ribociclib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to palbociclib for Other specified malignant neoplasms of breast
  94. Rituximab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
    Indications
    Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Burkitt lymphoma including Burkitt leukaemia Follicular lymphoma
  95. Tamoxifen General information
    Section
    Hormones and antihormones
    • Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
    Indications
    Malignant neoplasms of breast Other specified malignant neoplasms of breast
  96. Temozolomide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection
    • Oral > Solid > capsule: 5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg
    Indications
    Other specified gliomas of brain Neuroblastoma, NOS Unspecified malignant neoplasms of unspecified sites Ewing sarcoma of bone or articular cartilage of unspecified sites
  97. Thalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 50 mg
    Indications
    Plasma cell myeloma
  98. Tioguanine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 40 mg
    Indications
    Lymphoid leukaemia, not elsewhere classified
  99. Tisagenlecleucel General information
    Section
    Antineoplastics and supportive medicines
    Indications
    Therapeutic equivalent to axicabtagene ciloleucel for Diffuse large B-cell lymphomas
  100. Tislelizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 100 mg per 10 mL
    • Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion
    • Parenteral > General injections > IV: 100 mg per 10 mL contentrate for solution for infusion
    Indications
    Malignant neoplasms of urinary tract Squamous cell carcinoma of oesophagus Other specified malignant neoplasms of bronchus or lung Hodgkin lymphoma
  101. Toripalimab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 240 mg per 6 mL in vial
    Indications
    Squamous cell carcinoma of oesophagus Malignant neoplasms of nasopharynx
  102. Trametinib General information
    Section
    Targeted therapies
    • Oral > Solid: 0.5 mg; 2 mg
    Indications
    Other specified melanoma of skin
  103. Trastuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  104. Trastuzumab emtansine General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  105. Tremelimumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion
    Indications
    Hepatocellular carcinoma of liver Other specified malignant neoplasms of bronchus or lung
  106. Triptorelin General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate
  107. Vemurafenib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to dabrafenib for Other specified melanoma of skin
  109. Vincristine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)
    • Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
    Indications
    Other specified gliomas of brain Diffuse large B-cell lymphoma, not otherwise specified Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Langerhans cell histiocytosis Kaposi sarcoma of unspecified primary site Rhabdomyosarcoma primary site Hodgkin lymphoma Unspecified malignant neoplasms of unspecified sites Malignant trophoblastic neoplasms of placenta Follicular lymphoma Ewing sarcoma of bone or articular cartilage of unspecified sites Retinoblastoma Malignant neoplasms of kidney, except renal pelvis
  110. Vinorelbine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
    • Oral > Solid > capsule: 20 mg; 30 mg; 80 mg
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
    Indications
    Rhabdomyosarcoma primary site Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast
  111. Zanubrutinib General information
    Section
    Targeted therapies
    • Oral > Solid: 80 mg
    • Oral > Solid > capsule: 80 mg
    Indications
    Mantle cell lymphoma Therapeutic equivalent to ibrutinib for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  112. Zoledronic acid General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle
    Indications
    Malignant neoplasm metastasis in bone or bone marrow